Randomized trial evaluates the impact of macrophage signatures on liver disease staging in metabolic dysfunction, implying the need for non-invasive biomarkers.
The clinical management of metabolic dysfunction-associated steatohepatitis (MASH) hinges on accurate staging, yet liver biopsy remains the invasive gold standard (1). Non-invasive biomarkers that capture the dynamic interplay between metabolic stress and immune remodeling are urgently needed. The advent of high-throughput omics techniques, even at the single-cell or nuclear level, has shed light on the role of immune cells in metabolic dysfunction-associated steatotic liver disease (MASLD) and its progression to MASH (2).
No takes yet. Share an insight, caveat, or question.
Carlos J. Pirola (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: